Abstract 2118P
Background
The refeeding syndrome is a potentially lethal condition, associated with metabolic alterations after food reintroduction, and subsequent increase in nutritional intake. It occurs especially in malnourished patients, or in a hyper-catabolic stage. Particularly oncological diseases represent an increased risk factor for the manifestation of the syndrome. Data related to the oncological population is rarely reported, except for the various case series/case studies published to date.This study aims to determine the prevalence of refeeding syndrome in oncological patients according to their risk and to develop a clinical pathway to address and monitor this syndrome.
Methods
A prospective longitudinal study was carried out on 124 patients who started exclusive support via parenteral or enteral nutrition, in 4 units of the oncology hospital: intensive care, intermediate care, medical and surgical inpatient units. Risk for refeeding syndrome was determined as follows: low risk, moderate, high. Biochemistry available (ionogram) before feeding, and its evolution over the first 5 days after initiation was evaluated.
Results
In 64% of patients, serum phosphate, potassium, and magnesium measurements were available prior to nutritional support. There was no information on serum phosphate in 29.7% of patients, with no significant differences between surgical and medical patients. After 48 hours, serum concentration variations were especially pronounced in patients without electrolyte supplementation prior to feeding (-18.2%) versus previously supplemented (10.3%) (p=0.035). After 72 hours, 31.8% of patients experienced reductions superior to 30% in the ionogram, compatible with refeeding syndrome. A positive Spearman's correlation (0.69, p=0.017) was identified between the initially assessed risk (moderate and high) and the decrease in phosphate (>20%) observed at the end of 48 hours in non-supplemented patients.
Conclusions
There is a high prevalence of refeeding syndrome in cancer patients. Monitoring should be continuous, including hypophosphatemia. By providing a multidisciplinary intervention and allowing the provision of micronutrients at the appropriate time, complications of the syndrome can be avoided.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Instituto Português de Oncologia do Porto Francisco Gentil (IPO).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06